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Abstract
Background: Betulinic acid (BA) is a novel antineoplastic agent under evaluation for tumor therapy. Because of the
selective cytotoxic effects of BA in tumor cells (including gliomas), the combination of this agent with conservative
therapies (such as radiotherapy and chemotherapy) may be useful. Previously, the combination of BA with
irradiation under hypoxic conditions had never been studied.
Methods: In this study, the effects of 3 to 30 μM BA on cytotoxicity, migration, the protein expression of PARP,
survivin and HIF-1a, as well as radiosensitivity under normoxic and hypoxic conditions were analyzed in the
human malignant glioma cell lines U251MG and U343MG. Cytotoxicity and radiosensitivity were analyzed with
clonogenic survival assays, migration was analyzed with Boyden chamber assays (or scratch assays) and protein
expression was examined with Western blot analyses.
Results: Under normoxic conditions, a half maximal inhibitory concentration (IC50)o f2 3μMw a so b s e r v e di n
U251MG cells and 24 μM was observed in U343MG cells. Under hypoxic conditions, 10 μMo r1 5μMo fB A
showed a significantly increased cytotoxicity in U251MG cells (p = 0.004 and p = 0.01, respectively) and
U343MG cells
(p < 0.05 and p = 0.01, respectively). The combination of BA with radiotherapy resulted in an additive effect in
the U343MG cell line under normoxic and hypoxic conditions. Weak radiation enhancement was observed in
U251MG cell line after treatment with BA under normoxic conditions. Furthermore, under hypoxic conditions,
the incubation with BA resulted in increased radiation enhancement. The enhancement factor, at an irradiation
dose of 15 Gy after treatment with 10 or 15 μM BA, was 2.20 (p = 0.02) and 4.50 (p = 0.03), respectively.
Incubation with BA led to decreased cell migration, cleavage of PARP and decreased expression levels of
survivin in both cell lines. Additionally, BA treatment resulted in a reduction of HIF-1a protein under hypoxic
conditions.
Conclusion: Our results suggest that BA is capable of improving the effects of tumor therapy in human malignant
glioma cells, particularly under hypoxic conditions. Further investigations are necessary to characterize its potential
as a radiosensitizer.
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Glioblastoma is the most frequent primary brain tumor
and is characterized by a poor patient prognosis.
Although radiotherapy is widely used for the treatment
of patients with glioblastoma, the intrinsic radioresis-
tance of these tumors remains a critical problem in the
management of such patients [1]. Betulinic acid (BA)
represents a new therapeutic agent with possible use in
the treatment of glioblastoma. BA, a pentacyclic triter-
pene, can be synthesized by the oxidation of betulin, a
substance found in the bark of birch trees. Additionally,
it can also be directly isolated from certain plants. BA
has several therapeutic uses. It has been used to treat
inflammation, malaria, HIV and as an antimicrobial
drug. In addition, BA seems capable of improving tumor
therapies. For example, BA is cytotoxic in different
tumor cell lines, including neuroectodermal tumors,
melanoma, colon, lung and ovarian carcinoma, head and
neck cancers and sarcoma [2-4]. Experiments in animals
revealed that BA also has an antitumor effect in vivo
[5-7]. Interestingly, the cytotoxicity of BA in tumor cells
occurs regardless of whether there is a genetic defect in
p53 [6,8]. Remarkably, untransformed, normal cells (in
comparison to tumor cells) seem to tolerate relatively
high concentrations of BA. Thus, BA is not toxic up to
a concentration of 200-400 mg/kg of body weight in
rats or 500 mg/kg of body weight in mice [5,9].
Different studies have shown that BA induces apopto-
sis [8,10-13]. In addition, BA’s effects on cell migration,
cell invasion and angiogenesis inhibition have been
demonstrated [14-16]. Furthermore, reactive oxygen
radicals generated by BA have been shown to cause sig-
nificant DNA damage [17-19]. The finding that BA can
both induce the formation of reactive oxygen radicals
and induce apoptosis could make it attractive for the
treatment of hypoxic tumors. The role of hypoxia in
developing a more aggressive tumor phenotype in
glioma has been previously discussed [20-22]. Because
of the selective and wide-range cytotoxic effects of BA
in tumor cells, the combination of BA with conservative
therapies (such as radiotherapy and chemotherapy)
seemed like a promising therapeutic strategy to investi-
gate. Indeed, investigations have shown that BA
enhances the cytotoxic effects of vincristine in the
B16F10 melanoma cell line [7]. Additionally, sublines of
SNU-C5 colon cancer cells that are resistant to che-
motherapy showed a significantly increased cytotoxicity
when either 5-fluorouracil, irinotecan, or oxaliplatin
were combined with BA treatment [23]. Two studies
examining the combination of BA and radiotherapy (in
melanoma or head and neck cancer cell lines) detected
an additive effect on clonogenic survival [24,25]. How-
ever, there have been no studies examining BA treat-
ment in combination with irradiation under hypoxic
conditions. In this study, we analyzed the effects of BA
on the cytotoxicity, migration, protein expression of
PARP, survivin and HIF-1a and radiosensitivity under
normoxic and hypoxic conditions in the radioresistant
glioma U251MG and U343MG cell lines.
Methods
Cell culture conditions, treatments with BA and
irradiation
The human malignant glioma cell lines U251MG and
U343MG (American Type Culture Collection) were
grown in RPMI 1640 medium (Lonza, Walkersville, MD,
USA) containing 10% fetal bovine serum (PAA, Cölbe,
Germany), 1% sodium pyruvate (Invitrogen, Karlsruhe,
Germany), 185 U/ml penicillin (Invitrogen) and 185 μg/
ml streptomycin (Invitrogen) at 37°C in a humidified
atmosphere containing 3% CO2. Hypoxia (< 1% O2) was
achieved using a gas generator system as previously
described [26]. All experiments were performed with
cells in their logarithmic growth phase. BA (Biosolution
GmbH, Halle, Germany) was dissolved in dimethyl sulf-
oxide (DMSO) to achieve a 20 mM stock solution. Cells
(3 × 10
5) were seeded in 25 cm
2 flasks 24 h before treat-
ment with 3 to 30 μM BA. Cells were treated with BA
or DMSO for 24 h at 37°C under normoxic or hypoxic
conditions. Additionally, cells were irradiated in tissue
culture flasks (Greiner, Frickenhausen, Germany) with 2,
6o r1 5G y2 4ha f t e ri n c u b a t i o nw i t hB A .I r r a d i a t i o n
was accomplished with 6 MV photons and adequate
bolus material on a SIEMENS ONCOR (Erlangen, Ger-
many) linear accelerator at a dose rate of 2 Gy/min. At
1, 24 or 48 h after irradiation, cells were harvested for
clonogenic assays, protein extraction and migration
assays.
Clonogenic survival assays and radiosensitivity
The cytotoxicity of BA was evaluated using the clono-
genic survival assay. The cells were trypsinized 1 h after
irradiation. Based on the optimal plating efficacy
(depending on the BA treatment and irradiation dose),
500-5,000 cells were seeded in 25 cm
2 flasks. The cells
were cultured in RPMI supplemented with 10% FCS in
a humidified atmosphere of 3% CO2 at 37°C. The med-
ium was changed after 5 days. Between 10 and 14 days
after irradiation, the cells were fixed with paraformalde-
hyde (Sigma, Deisenhofen, Germany), and colony forma-
tion was visualized by staining with 10% Giemsa
solution (Sigma, Deisenhofen, Germany). Only colonies
with > 50 cells were scored to determine the surviving
fraction (SF). The cytotoxicity of BA was defined as the
ratio of colonies formed after treatment with different
concentrations of BA to DMSO-treated control cells.
The SF was defined as the ratio of colonies formed after
irradiation with 0, 2, 6 or 15 Gy to the number of
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enhancement factor (EF) was defined as the ratio of the
SF of BA-treated cells to DMSO-treated control cells
dependent on the dose of irradiation. The data represent
at least three independent experiments.
Migration assays and cell cycle analysis
Cell migration was assessed using modified Boyden
chambers as previously described [27]. Cells (2 × 10
4)
were suspended in 300 μl of RPMI without FCS and
were then added to the upper chamber (membrane filter
with 8 μm pore size), while the bottom chamber was
filled with 1 ml of RPMI supplemented with 20% FCS
(as a chemoattractant). The assay was performed at 37°
C in a humidified atmosphere containing 3% CO2 for at
least 16 h. Non-migrating cells on the upper side of the
transwell inserts were removed. The cells that had
migrated to the bottom side of the membrane were
trypsinized and counted with CASY DT (Schärfe System
GmbH, Reutlingen, Germany). The data represent at
least three independent experiments.
Furthermore, we used a wound scratch assay to deter-
mine the migration of cells after treatment with BA.
Cells were grown in 6-well cell culture plates in RPMI
medium containing 10% FCS and were cultured to 100%
confluence. A uniform cell-free area was created by
scratching the confluent monolayer with a 200 μl pipette
tip. To determine the migration of glioma cells, the
wound closure was observed at different time points.
The wound scratch assay was performed three times in
independent experiments.
Cells were analyzed for cell cycle distribution. About 5
×1 0
5 cells were harvested and washed in PBS. Subse-
quently, 95% ethanol was added slowly until a final con-
centration of 80% was reached. The DNA content,
which was indicated by the extent of staining of propi-
dium iodide, was measured by flow cytometry in an
FACSscan (Becton Dickinson, Heidelberg, Germany),
using the CellFit software (Version 2.0).
Western blotting
Cells were washed, trypsinized and centrifuged. The
supernatant of cells was washed with PBS and resus-
pended in 100 μlo fl y s i sb u f f e r( 5 0m MT r i sa tp H8 . 0 ,
0.3 M NaCl, 1 mM EDTA, 0.5 mM dithiothreitol, 0.1%
NP40 and protease inhibitors), followed by ultrasonic
homogenization. After centrifugation at 14,000 g for 15
min, the supernatant was collected and the protein con-
centration was determined using the Bradford assay
(BioRad, Munich, Germany). About 30 μg of total pro-
tein from each cell lysate was separated on a 10%
NuPAGE Bis-Tris (Invitrogen) gel that was placed in an
X-Cell SureLock Mini-Cell (Invitrogen). The membrane
was blocked with 10% non-fat milk in TBST (50 mM
N a C l ,3 0m MT r i s - H C la tp H8 . 0a n d0 . 1 %T w e e n )f o r
1 h and incubated with rabbit anti-human survivin anti-
body (1:1,000 dilution, clone AF886, R&D Systems,
Wiesbaden, Germany), rabbit anti-human cleaved PARP
(1:2,000, Cell Signaling, Danvers, MA, USA), mouse
anti-human HIF1a antibody (1:1,000, BD Transduction
Laboratories, Lexington, KY) and mouse anti-b-actin
(1:5,000, Sigma, Deisenhofen, Germany) at 4°C over-
night. After washing, the membranes were incubated
with a horseradish peroxidase-labeled goat anti-rabbit or
anti-mouse IgG (1:2,000, DAKO, Glostrup, Denmark)
for 1 h at room temperature. For protein detection,
membranes were incubated with ECL substrate or ECL
Plus Blotting Detection System for 1 min (Amersham
Pharmacia Biotech, Freiburg, Germany) and exposed to
X-ray film (Biomax, Kodak, Braunschweig, Germany).
Statistical analyses
The experimental results were analyzed by paired Stu-
dent’s t-tests. A p-value of 0.05 was considered to be
significant.
Results
Effects of BA on clonogenic survival
The effects of BA on the clonogenic survival, cell migra-
tion, cell cycle, protein expression and radiosensitivity in
U251MG and U343MG glioma cell lines under nor-
moxic and hypoxic conditions were determined. With
higher concentrations (from 3 - 30 μM), a decline in
clonogenic survival was observed, with an IC50 of 23
μM in U251MG cells and 24 μM in U343MG cells
under normoxic conditions after an incubation time of
24 h (Figure 1). In addition, longer incubation with BA
led to increased cytotoxicity in both cell lines (data not
shown). Additionally, incubation of BA caused an
increase of subG1-cells in both cell lines. However, we
did not find effects of BA on cell distribution in other
cell cycle phase (data not shown). Under hypoxic condi-
tions, BA had significantly increased cytotoxicity in both
glioma cell lines (Figure 2). After a 24 h incubation with
10 μMo r1 5μM BA under normoxic conditions, the
clonogenic survival was reduced to 79% (p = 0.07) or
57% (p = 0.03) in U251MG cells and 87% (p = 0.15) or
82% (p = 0.07) in U343MG cells, respectively. Under
hypoxic conditions, an increased reduction in survival to
30% (p = 0.01) or 9% (p = 0.03) and 46% (p = 0.10) or
0.8% (p = 0.03), respectively, was detected (Figure 2).
Effects of BA on cell migration and protein expression
The effects of BA on the migration rates of both glioma
cell lines were determined with the Boyden chamber
assay and the scratch assay. Decreased migration rates
were detected after incubation with a higher concentra-
tion of BA in both cell lines. Compared to DMSO-
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Figure 1 Cytotoxicity in U251MG and U343MG cell lines after treatment with BA. Both glioma cell lines were treated with increasing doses
of BA from 3 - 30 μM. The half maximal inhibitory concentration (IC50) with an incubation time of 24 h was 24 μM in U343MG cells and 23 μM
in U251MG cells. Data represent mean values (± SD) of three independent experiments.
Figure 2 Effects of BA on clonogenic survival of glioma cells under normoxic or hypoxic conditions. Clonogenic survival in U251MG (A)
and U343MG (B) cells after treatment with 10 or 15 μM BA under normoxic or hypoxic conditions. Under hypoxia, when compared to normoxic
conditions, BA showed increased cytotoxicity in both glioma cell lines. Data represent mean values (± SD) of three independent experiments (*
p < 0.05).
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Page 4 of 9treated control cells, incubation with 5, 10 and 20 μM
BA led to decreased cell migration rates in U251MG
cells to 92% (p = 0.21), 87% (p = 0.12) and 67% (p =
0.09), or in U343MG cells to 93% (p = 0.10), 70% (p =
0.20) and 53% (p = 0.08), respectively, under normoxic
conditions (Figure 3A). Similarly, reduced migration
rates were found after cells were incubated with BA in
the scratch assay (Figure 3B).
Using Western blot analysis, we examined the clea-
vage of PARP (as an indicator for the induction of apop-
tosis) and the expression of survivin (as an inhibitor of
apoptosis) (Figure 4). Incubation with 20 or 25 μMB A
led to PARP’s cleavage, and to a decrease in survivin
levels under normoxic conditions. Additionally,
increased PARP’s cleavage and a decrease in survivin
protein levels were observed after treatment with 10 or
15 μM BA in the U251MG cells under hypoxic condi-
tions. BA also decreased hypoxia-induced levels of the
HIF-1a protein in both cell lines (Figure 4). However,
combination of BA with radiotherapy showed no addi-
tional effects on PARP cleavage or the expression of sur-
vivin under normoxic or hypoxic conditions.
Effects of BA on radiosensitivity
Irradiation at 2 Gy reduced clonogenic survival to 70%
(SF2 = 0.70) in U251MG cells and 71% (SF2 = 0.71) in
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Figure 3 Effects of BA on cell migration of glioma cells. Migration rates of U251MG and U343MG cells treated with BA analyzed by Boyden
chamber assays (A) and scratch assays (B) under normoxic conditions. Compared to DMSO-treated control cells, incubation with 5, 10 and 20
μM BA led to a decrease in cell migration rates in both glioma cell lines. Similarly, cells had a reduced migration rate after BA treatment as
measured by the scratch assay. Data represent the average values (± SD) of three independent experiments.
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induced clonogenic survival of U251MG and U343MG
cells was increased under hypoxic conditions when com-
pared to normoxic conditions (Figure 5). The combina-
tion of BA with radiotherapy resulted in an additive
effect for U343MG cells under normoxic and hypoxic
conditions. However, a weak not significant radioprotec-
tive effect was observed at 10 μMB Au n d e rh y p o x i c
conditions. In addition, a weak radiation enhancement
was observed for U251MG cells under normoxic condi-
tions. The enhancement factor at a radiation dose of 6
Gy after treatment with 20 μMa n d2 5μM BA was 1.22
(p = 0.02) and 1.34 (p = 0.15), respectively (Figure 5).
However, under hypoxic conditions, the effects of BA
on radiosensitivity were strongly enhanced in U251MG
cells. The enhancement factor at an irradiation dose of
15 Gy after 10 μMo r1 5μM BA treatment was 2.20 (p
= 0.02) and 4.50 (p = 0.03), respectively (Figure 5).
Discussion
Betulinic acid (BA) represents a new therapeutic agent
with possible uses in the treatment of glioblastoma [10].
Because of the selective cytotoxic effects of BA in tumor
cells, combining BA treatment with conservative tumor
therapies (such as radiotherapy and chemotherapy) is
attractive. Here, we report that BA triggers cytotoxicity
in human malignant glioma cells in a dose-dependent
manner (Figure 1). In addition, the cytotoxic effects of
BA were increased in both cell lines under hypoxic con-
ditions (Figure 2). In accordance with our investigations,
BA was found to be a highly potent cell-death promot-
ing agent in primary glioblastoma cells and cell lines
[10,28]. However, 17% (4 of 24) primary glioblastoma
cells did not respond to treatment with BA [10]. An
activated EGFR/AKT pathway and the expression of sur-
vivin contributed to a lower sensitivity in response to
BA treatment in human melanoma cells [29].
In the present study, the increased cytotoxicity in both
glioma cell lines was dependent on BA concentration.
Additionally, it was coupled with an inhibition of cell
migration, the cleavage of the apoptotic protein PARP
and a decrease in the protein level of the apoptosis inhi-
bitor survivin (Figure 3 and 4). In agreement with our
current findings, BA was also found to inhibit the migra-
tion of glioma (C6), lung carcinoma (A549) and medullo-
blastoma (TE671) cells [15]. In addition, BA-induced
inhibition of migration was associated with the suppres-
sion of mRNA and protein levels of MMP-2 and MMP-9
in vascular smooth muscle cells [30]. It is well known
that the activation of these two matrix metalloproteinases
is involved in cellular invasion and migration. Recent stu-
dies also detected BA as an inhibitor of migration, inva-
sion and angiogenesis [14,16]. Furthermore, different
analyses have shown that BA induces apoptosis in tumor
cell lines [8,11,12,31]. BA-induced apoptosis can be asso-
ciated with cytochrome c release, the activation of cas-
pases, the cleavage of PARP and modulation of Bcl2
family protein levels in glioma cells [10,17,32]. However,
overexpression of the anti-apoptotic protein Bcl-2 only
partially delayed the induction of apoptosis in Jurkat cells
Figure 4 Effects of BA and irradiation on protein expression levels of glioma cells. BA treatment affects the cleavage of PARP, the
expression of survivin and hypoxia-induced HIF-1a protein levels in U251MG (left) and U343MG (right) cells. Cell lines were untreated (UT),
treated with DMSO or with increasing doses of BA from 10, 20 or 25 μM under normoxic conditions (A, B) and untreated (UT), treated with
DMSO or with doses of 10 or 15 μM BA plus irradiation at 15 Gy under hypoxic conditions (C, D). Actin served as an internal loading control.
The Western blot shows one representative result out of three independent experiments.
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and neck cancer cells, BA-induced cytotoxic effects were
linked to a decreased level of Bax, an inducer of apoptosis
[33]. In prostate cancer cells, the combination of doce-
taxel and BA increased NF- B activity and stimulated
apoptosis [34]. Altogether, the exact mechanisms by
which BA might act as an effective and wide-range anti-
cancer agent remain unclear.
First investigations studying the effect of BA treatment
in combination with other chemotherapeutic drugs
showed that BA improved the cytotoxic effects of differ-
ent agents. In the mouse melanoma cell line B16F10,
BA improved vincristine-induced cytotoxic effects in
vitro, in addition to reducing the number of metastases
in vivo [7]. Sublines of the colon cancer cell line SNU-
C5 that are resistant to chemotherapy showed
Figure 5 Effects of BA on radiosensitivity of glioma cells. U251MG (left) and U343MG (right) cells were either treated with 10, 20 or 25 μM
BA and irradiated with a dose of 2 and 6 Gy under normoxic conditions (A, B), or treated with 5, 10 or 15 μM BA and irradiated with a dose of
6 and 15 Gy under hypoxic conditions (C, D) and compared to DMSO-treated control cells. Data represent the mean values (± SD) of three
independent experiments.
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irinotecan or oxaliplatin were combined with BA treat-
ment [23]. In addition, BA augmented doxorubicin- or
cisplatin-induced apoptosis in several different tumor
cell lines, while no apoptosis was induced by BA treat-
ment in untransformed fibroblasts [31]. However, the
addition of BA in SCC9 and SCC25 head and neck
tumor cell lines had no effects on cisplatin-induced
apoptosis [35]. In recent studies, glioma cell lines were
characterized as radioresistant, with a low rate of irra-
diation-induced apoptosis [36-38]. Our analyses show
that BA, in combination with radiotherapy, resulted in
an additive effect for the U343MG cells and a weak
radiation enhancement for U251MG cells under nor-
moxic conditions (Figure 5). This is in agreement with
two studies that dealt with testing a combination of BA
treatment and radiotherapy for its effects on two mela-
noma [24] and two head and neck cancer cell lines [25].
These studies showed that these two treatments were
more effective in combination. The present data also
demonstrate that BA strongly enhances the radiosensi-
tivity of U251MG cells under hypoxic conditions (Figure
5). To our knowledge, this is the first study demonstrat-
ing that BA can increase cytotoxicity and radiosensitivity
under hypoxic conditions. These effects are coupled
with the inhibition of the hypoxia-induced increase of
HIF-1a protein level (Figure 4). In accordance with
results presented here, a decrease of HIF-1a after BA
treatment has been described in adenocarcinoma cells
[39]. Recently, our group showed that the silencing of
HIF-1a by siRNA or chetomin resulted in a significantly
enhanced cytotoxicity and radiosensitivity in both
human glioma cell lines [38], in addition to HT1080
human fibrosarcoma cells [40,41]. The downregulation
of HIF-1a consistently increased the sensitivity of
human glioma cells to doxorubicin and etoposide [42].
Conclusions
In summary, BA affects the clonogenic survival, migra-
tion and apoptosis in human malignant glioma cells.
Remarkably, additional effects on cytotoxicity and radia-
tion sensitivity were observed under hypoxic conditions.
T h e s er e s u l t ss u g g e s tt h a tB Am a yb es u i t a b l ef o r
improving the treatment of malignant gliomas. However,
more investigations are necessary to characterize its role
as chemotherapeutic drug and potential radiosensitizer.
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